Literature DB >> 23331460

Quercetin decreases liver damage in mice with non-alcoholic steatohepatitis.

Eder Marcolin1, Luiz Felipe Forgiarini, Graziella Rodrigues, Juliana Tieppo, Greice Stefani Borghetti, Valquiria Linck Bassani, Jaqueline Nascimento Picada, Norma Possa Marroni.   

Abstract

Non-alcoholic steatohepatitis (NASH) is a frequent condition in obese patients that may progress to end-stage liver disease. This study was designed to evaluate the modulation of this condition by use of quercetin (Q), a flavonoid largely found in vegetable foods, with known anti-inflammatory and antioxidant properties, in the experimental model of non-alcoholic steatohepatitis (NASH) using a diet deficient in methionine and choline (MCD). Male C57BL6 mice were divided into four groups (n = 16): (i) Control plus vehicle (control ration plus carboxymethylcellulose 1% used as vehicle, CO + V); (ii) Control ration plus Q 50 mg/kg (CO + Q); (iii) MCD diet plus vehicle (NASH + V); and (iv) MCD diet plus Q (NASH + Q). Diets were administered for 4 weeks. At the end of the experimental period, liver alterations, bioindicators of oxidative stress and DNA damage were assessed. NASH was diagnosed in 100% of the mice that were fed the MCD diet. In addition, a significant increase in DNA damage in liver tissue from NASH + V group was observed in comparison with CO + V. The group NASH + Q showed a significant decrease in hepatic damage enzymes, lipoperoxidation, DNA damage and a lower degree of macrovesicular steatosis, ballooning and inflammatory process. These findings suggest that Q may have protective effects by improving liver integrity in NASH.
© 2013 Nordic Pharmacological Society. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23331460     DOI: 10.1111/bcpt.12049

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  11 in total

Review 1.  DNA damage response and sphingolipid signaling in liver diseases.

Authors:  Masayuki Nagahashi; Yasunobu Matsuda; Kazuki Moro; Junko Tsuchida; Daiki Soma; Yuki Hirose; Takashi Kobayashi; Shin-Ichi Kosugi; Kazuaki Takabe; Masaaki Komatsu; Toshifumi Wakai
Journal:  Surg Today       Date:  2015-10-29       Impact factor: 2.549

2.  Effects of the compounds resveratrol, rutin, quercetin, and quercetin nanoemulsion on oxaliplatin-induced hepatotoxicity and neurotoxicity in mice.

Authors:  Tania E Schwingel; Caroline P Klein; Natalia F Nicoletti; Cristiana L Dora; Gabriela Hadrich; Cláudia G Bica; Tiago G Lopes; Vinicius Duval da Silva; Fernanda B Morrone
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-06-08       Impact factor: 3.000

3.  The Effects of Onion Consumption on Prevention of Nonalcoholic Fatty Liver Disease.

Authors:  Hadi Emamat; Forough Foroughi; Hassan Eini-Zinab; Azita Hekmatdoost
Journal:  Indian J Clin Biochem       Date:  2017-01-10

Review 4.  Effects of resveratrol and other polyphenols in hepatic steatosis.

Authors:  Leixuri Aguirre; Maria Puy Portillo; Elizabeth Hijona; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

5.  Quercetin Alleviates High-Fat Diet-Induced Oxidized Low-Density Lipoprotein Accumulation in the Liver: Implication for Autophagy Regulation.

Authors:  Liang Liu; Chao Gao; Ping Yao; Zhiyong Gong
Journal:  Biomed Res Int       Date:  2015-12-01       Impact factor: 3.411

Review 6.  Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects.

Authors:  Ravirajsinh Jadeja; Ranjitsinh V Devkar; Srinivas Nammi
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-03       Impact factor: 2.629

7.  Protective role of quercetin against manganese-induced injury in the liver, kidney, and lung; and hematological parameters in acute and subchronic rat models.

Authors:  Entaz Bahar; Geum-Hwa Lee; Kashi Raj Bhattarai; Hwa-Young Lee; Hyun-Kyoung Kim; Mallikarjun Handigund; Min-Kyung Choi; Sun-Young Han; Han-Jung Chae; Hyonok Yoon
Journal:  Drug Des Devel Ther       Date:  2017-09-05       Impact factor: 4.162

8.  Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis.

Authors:  Munkhzul Ganbold; Yohei Owada; Yusuke Ozawa; Yasuhiro Shimamoto; Farhana Ferdousi; Kenichi Tominaga; Yun-Wen Zheng; Nobuhiro Ohkohchi; Hiroko Isoda
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379

9.  Dietary component isorhamnetin is a PPARγ antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency.

Authors:  Yu Zhang; Ming Gu; Wujie Cai; Lijing Yu; Li Feng; Lu Zhang; Qingqing Zang; Yahui Wang; Dongshan Wang; Hui Chen; Qingchun Tong; Guang Ji; Cheng Huang
Journal:  Sci Rep       Date:  2016-01-18       Impact factor: 4.379

Review 10.  Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non-Alcoholic Fatty Liver Disease.

Authors:  Ayokanmi Ore; Oluseyi Adeboye Akinloye
Journal:  Medicina (Kaunas)       Date:  2019-01-24       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.